PTRK PHYSITRACK PLC

Global Virtual Care Provider Physitrack Comes to Italy

MILAN & LONDON--(BUSINESS WIRE)--

Physitrack, the world-leading provider of technology for Virtual Care, and the main provider of remote patient engagement solutions to physiotherapy providers during the Covid-19 pandemic, continues its global expansion by launching in the Italian market.

Furthering its commitment to help healthcare professionals around the world provide virtual care, Physitrack has developed a fully translated Italian version of its patient engagement and Telehealth solution and hereby announces its launch in the Italian market.

Says Henrik Molin, CEO and co-founder of Physitrack: "We are very excited to offer our award-winning technology to over 60 million Italians at a time when they bravely fight the devastating effects of the Covid-19 global pandemic. Our solutions are applicable for acute, post-acute and chronic musculoskeletal and neurological conditions, and can help patients who are subject to social distancing and isolation in this unprecedented period."

Most notably, Physitrack will offer Italian care providers completely free usage of the system for up to 30 days after they subscribe to the service, as well as free, unlimited Telehealth as part of Physitrack’s recently announced Telehealth Basic offering.

Physitrack's Italian expansion efforts will be lead by a local team, with the support and assistance of Physitrack's teams on five continents.

For further information, please visit

Physitrack is an Apple (NASDAQ: AAPL) Mobility Partner and the world leader in the provision of Virtual Care technology. Physitrack works with tens of thousands of public and private healthcare providers around the world that cares for several million patients in over 100 countries.

EN
02/11/2020

Underlying

PTRKPHYSITRACK PLC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on PHYSITRACK PLC

Joachim Gunell
  • Joachim Gunell
Free Trial
PTRK PHYSITRACK PLC

Physitrack (No_rec, TP: SEK) - Discontinuing coverage

We have discontinued our regular coverage of Physitrack, and our last published recommendation, target price and estimates should no longer be relied upon. Going forward, we plan to cover Physitrack ‘powered by Redeye’.

06/28/23 June 28, 2023 1 EN
Alexander Aukner ... (+9)
  • Alexander Aukner
  • Håkon Astrup
  • Hanna Lindbo
  • Helene Kvilhaug Brøndbo
  • Joachim Gunell
  • Jørgen Lian
  • Martin Hoang Nguyen
  • Ole Martin Westgaard
  • Ole-Andreas Krohn
ORK ORKLA ASA
ALIG ALIMAK GROUP AB
BAKKA BAKKAFROST P/F
VOW VOW ASA
FKRFT FJORDKRAFT HOLDING ASA
AXA AXACTOR SE
CAMBI CAMBI
MPCC MPC CONTAINER SHIPS AS
HPUR HEXAGON PURUS
PTRK PHYSITRACK PLC
05/10/23 May 10, 2023 1 EN
Joachim Gunell
  • Joachim Gunell
Free Trial
PTRK PHYSITRACK PLC

Physitrack (Buy, TP: SEK34.00) - At the profitability trough

We see Physitrack’s Q1 results as a step in the right direction but believe management will have to continue to demonstrate that it can balance its high growth ambitions with a trough in EBITDA margins and cash flows over the coming quarters to ease investor concerns about funding. We reiterate our BUY but have cut our target price to SEK34 (40), as we see fundamental upside potential in the stock, although we acknowledge that the limited liquidity caps the potential investor base at this stage.

05/09/23 May 9, 2023 1 EN
Joachim Gunell ... (+5)
  • Joachim Gunell
  • Jørgen Lian
  • Martin Huseby Karlsen
  • Ole-Andreas Krohn
  • Patrik Ling
NEL NEL ASA
FRO FRONTLINE LTD.
VICO VICORE PHARMA HOLDING AB
AVACF AVANCE GAS HOLDINGS LTD
MPCC MPC CONTAINER SHIPS AS
HAFNI HAFNIA
PTRK PHYSITRACK PLC
03/01/23 March 1, 2023 1 EN
Joachim Gunell
  • Joachim Gunell
Free Trial
PTRK PHYSITRACK PLC

Physitrack (Buy, TP: SEK40.00) - FCF break-even needed

Physitrack continues to show solid revenue growth, though incremental margins and cash flow remain below our expectations as a result of the ongoing revenue mix shift and higher investments needed to consolidate recent acquisitions into one holistic wellness platform. We believe we are at a trough for negative margin and cash flow progression, but see a potential share-price catalyst in FCF reaching break-even in H2 2023e. The stock is trading close to the ~SEK15 level at which the co-founders c...

02/28/23 February 28, 2023 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch